

## APC anti-mouse Ly-6A/E (Sca-1) Antibody

<b>Catalog# / Size</b>	108111 / 25 µg 108112 / 100 µg
<b>Clone</b>	D7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Sca-1
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	Ly-6A/E, also known as Sca-1, is an 18 kD member of the Ly-6 multigene family. Ly6A/E is a glycosylphosphatidylinositol (GPI)-linked protein expressed on hematopoietic stem cells. In mice expressing the Ly-6.2 haplotype (e.g., AKR, C57BL, C57BR, DBA/2, SJL, SWR, and 129), Ly-6A/E is also expressed on peripheral B lymphocytes and thymic and peripheral T lymphocytes. Strains expressing the Ly-6.1 haplotype (e.g., BALB/c, CBA, C3H/He, DBA/1, and NZB) have low Ly-6A/E expression on resting peripheral lymphocytes. The expression of Ly-6A/E on lymphocytes is upregulated upon activation from both Ly6.1 and Ly6.2 haplotype mice. Ly-6A/E is thought to be involved in the regulation of both T and B cell responses.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	IL-2-dependent mouse T-cell line (CTL-L)
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting <sup>1,2</sup> , immunoprecipitation <sup>1</sup> , <i>in vitro</i> lymphocyte activation <sup>3-6</sup> , induction of redirected lysis <sup>7</sup> , induction of T cell inhibitory signalling <sup>8</sup> , immunofluorescence <sup>9</sup> , and immunohistochemical staining of acetone-fixed frozen sections <sup>13</sup> and Bouin-fixed, paraffin-embedded samples <sup>9</sup> .  The two Sca-1 recognizing clones D7 and <a href="#">E13-161.7</a> have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7. <sup>14</sup>
<b>Application References</b>	<ol style="list-style-type: none"> <li>Ortega G, <i>et al.</i> 1986. <i>J. Immunol.</i> 137:3240. (WB, IP)</li> <li>Palfree RGE, <i>et al.</i> 1986. <i>Immunogenetics</i> 23:197. (WB)</li> <li>Codias EK, <i>et al.</i> 1990. <i>J. Immunol.</i> 144:2197.</li> <li>Malek TR, <i>et al.</i> 1986. <i>J. Exp. Med.</i> 164:709.</li> <li>Codias EK, <i>et al.</i> 1990. <i>J. Immunol.</i> 145:1407.</li> <li>Ivanov V, <i>et al.</i> 1994. <i>J. Immunol.</i> 153:2394.</li> <li>Karlhofer FM, <i>et al.</i> 1991. <i>J. Immunol.</i> 146:3662.</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

8. Fleming T, *et al.* 1994. *J. Immunol.* 153:1955.
9. van Bragt MPA, *et al.* 2005. *Biol. Reprod.* 73:634. (IF, IHC)
10. Umland O, *et al.* 2007. *J. Immunol.* 178:4147.
11. Cridland SO, *et al.* 2009. *Blood Cell. Mol. Dis.* 45:149. (FC) [PubMed](#)
12. Pronk CJ, *et al.* 2011. *J. Exp Med.* [PubMed](#)
13. English A, *et al.* 2000. *J. Immunol.* 165:3763. (IHC)
14. Bamezai A and Rock KL. 1995. *Proc. Natl. Acad. Sci. USA* 92:4294.
15. Wiesner DL, *et al.* 2015. *PLoS Pathog.* 11:1004701. [PubMed](#)

## Product Citations

1. Philpott J, *et al.* 2022. *Immunohorizons.* 6:366. [PubMed](#)
2. Mikami Y, *et al.* 2021. *Immunity.* 54(3):514-525.e6. [PubMed](#)
3. Umland O, *et al.* 2007. *J Immunol.* 178:4147. [PubMed](#)
4. Ju W, *et al.* 2020. *J Biomed Sci.* 27:91. [PubMed](#)
5. Viny AD, *et al.* 2019. *Cell Stem Cell.* 25:682. [PubMed](#)
6. Shi Y, *et al.* 2020. *Med Sci Monit.* 26:e923328. [PubMed](#)
7. Bo Yu *et al.* 2018. *Cell stem cell.* 23(2):193-209. [PubMed](#)
8. Nguyen N, *et al.* 2022. *iScience.* 25:103679. [PubMed](#)
9. Hinterbrandner M, *et al.* 2021. *JCI Insight.* 6:e151797. [PubMed](#)
10. Larouche JA, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
11. Fujino T, *et al.* 2021. *Nat Commun.* 12:1826. [PubMed](#)
12. Liu X, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
13. Yamamoto K, *et al.* 2021. *Cell Reports.* 36(8):109576. [PubMed](#)
14. Mann M, *et al.* 2018. *Cell Rep.* 25:2992. [PubMed](#)
15. Yin N *et al.* 2019. *Cancer Cell.* 36(2):156-167. [PubMed](#)
16. Fukushima T, *et al.* 2019. *Cell Rep.* 29:4144. [PubMed](#)
17. Endo Y, *et al.* 2020. *FASEB J.* 34:16086. [PubMed](#)
18. Vannini N, *et al.* 2019. *Cell Stem Cell.* 24:405. [PubMed](#)
19. De S, *et al.* 2018. *Development.* 145. [PubMed](#)
20. Wiesner D, *et al.* 2015. *PLoS Pathog.* 11:1004701. [PubMed](#)
21. Kunimoto H, *et al.* 2018. *Cancer Cell.* 33:44. [PubMed](#)
22. Hillel-Karniel C, *et al.* 2020. *Cell Reports.* 30(3):807-819.e4. [PubMed](#)
23. Shcherbina A, *et al.* 2020. *Cell Rep.* 32:107964. [PubMed](#)
24. Morimoto A, *et al.* 2021. *Nat Commun.* 12:2136. [PubMed](#)
25. Ferreirinha P, *et al.* 2022. *Development.* 149. [PubMed](#)
26. Derecka M, *et al.* 2020. *Nat Immunol.* 26:21. [PubMed](#)
27. Jungwirth N *et al.* 2018. *Journal of molecular neuroscience : MN.* 65(1):60-73. [PubMed](#)
28. Hou M, *et al.* 2020. *Stem Cell Res Ther.* 11:55. [PubMed](#)
29. Tavakol DN, *et al.* 2021. *Curr Protoc.* 1:e275. [PubMed](#)
30. Hepler C *et al.* 2018. *eLife.* 7 pii: e39636. [PubMed](#)
31. Ikram M, *et al.* 2018. *Oncotarget.* 9:2058. [PubMed](#)
32. Mizbani A, *et al.* 2016. *Development.* 143: 4137 - 4148. [PubMed](#)
33. Ding P, *et al.* 2022. *Bone Res.* 10:42. [PubMed](#)
34. Gentek R, *et al.* 2018. *Immunity.* 48:1160. [PubMed](#)
35. Goldstein JM *et al.* 2019. *Cell reports.* 27(4):1254-1264. [PubMed](#)
36. Luo H, *et al.* 2020. *Cancer Cell.* 36(6):645-659.e8. [PubMed](#)
37. Luo H, *et al.* 2022. *Mol Cell.* 82:833. [PubMed](#)
38. Keerthivasan S, *et al.* 2021. *Immunity.* 54(7):1511-1526.e8. [PubMed](#)
39. Bastianutto C, *et al.* 2007. *Cancer Res.* 67:10112. [PubMed](#)
40. Glotzbach J, *et al.* 2011. *PLoS One.* 6:e21211. [PubMed](#)
41. Wolock SL, *et al.* 2019. *Cell Rep.* 28:302. [PubMed](#)
42. Rodríguez L, *et al.* 2021. *Biomolecules.* 11: [PubMed](#)
43. Singhal P, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 122 - 127. [PubMed](#)
44. Markworth JF, *et al.* 2020. *JCI Insight.* 5:00. [PubMed](#)
45. Wong J, *et al.* 2016. *Sci Signal.* 9: ra103. [PubMed](#)
46. Vannini N, *et al.* 2016. *Nat Commun.* 7:13125. [PubMed](#)
47. Vogiatzi A, *et al.* 2021. *Mol Cell Biol.* 41:e0014921. [PubMed](#)
48. Liu Q, *et al.* 2016. *Cell Death Dis.* 1.93125. [PubMed](#)
49. Zhang Y, *et al.* 2008. *Mol Cell Biol.* 28:1688. [PubMed](#)
50. Thomson CA, *et al.* 2018. *J Immunol.* 201:215. [PubMed](#)
51. Cohen I *et al.* 2018. *Cell stem cell.* 22(5):726-739. [PubMed](#)

## RRID

AB\_313348 (BioLegend Cat. No. 108111)  
 AB\_313349 (BioLegend Cat. No. 108112)

## Antigen Details

---

<b>Structure</b>	Ly-6 multigene family, 18 kD
<b>Distribution</b>	Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells
<b>Function</b>	Regulates B and T cell responses
<b>Cell Type</b>	B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells
<b>Biology Area</b>	Immunology, Stem Cells

## Antigen References

1. Rock KL, *et al.* 1989. *Immunol. Rev.* 111:195.
2. Morrison SJ, *et al.* 1994. *Immunity* 1:661.
3. Spangrude GJ, *et al.* 1988. *J. Immunol.* 141:3697.
4. Malek T, *et al.* 1986. *J. Exp. Med.* 164:709.

## Gene ID

[110454](#)


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse Ly-6A/E (Sca-1), Biotin anti-mouse Ly-6A/E (Sca-1), FITC anti-mouse Ly-6A/E (Sca-1), PE anti-mouse Ly-6A/E (Sca-1), PE/Cyanine5 anti-mouse Ly-6A/E (Sca-1), Purified anti-mouse Ly-6A/E (Sca-1), PE/Cyanine7 anti-mouse Ly-6A/E (Sca-1), Alexa Fluor® 488 anti-mouse Ly-6A/E (Sca-1), Alexa Fluor® 647 anti-mouse Ly-6A/E (Sca-1), Pacific Blue™ anti-mouse Ly-6A/E (Sca-1), Brilliant Violet 421™ anti-mouse Ly-6A/E (Sca-1), PerCP anti-mouse Ly-6A/E (Sca-1), PerCP/Cyanine5.5 anti-mouse Ly-6A/E (Sca-1), APC/Cyanine7 anti-mouse Ly-6A/E (Sca-1), Brilliant Violet 510™ anti-mouse Ly-6A/E (Sca-1), Brilliant Violet 711™ anti-mouse Ly-6A/E (Sca-1), Brilliant Violet 605™ anti-mouse Ly-6A/E (Sca-1), Purified anti-mouse Ly-6A/E (Sca-1) (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse Ly-6A/E (Sca-1), Brilliant Violet 785™ anti-mouse Ly-6A/E (Sca-1), Alexa Fluor® 700 anti-mouse Ly-6A/E (Sca-1), Brilliant Violet 650™ anti-mouse Ly-6A/E (Sca-1), APC/Fire™ 750 anti-mouse Ly-6A/E (Sca-1), TotalSeq™-A0130 anti-mouse Ly-6A/E (Sca-1), TotalSeq™-B0130 anti-mouse Ly-6A/E (Sca-1), TotalSeq™-C0130 anti-mouse Ly-6A/E (Sca-1)

## Product Data



C57BL/6 mouse splenocytes stained with D7 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587